S&P 500   3,967.71 (+0.48%)
DOW   32,210.87 (+0.33%)
QQQ   310.45 (+0.23%)
AAPL   159.76 (+0.52%)
MSFT   279.75 (+0.75%)
META   206.10 (+0.89%)
GOOGL   105.25 (-0.33%)
AMZN   98.09 (-0.63%)
TSLA   190.11 (-1.10%)
NVDA   267.53 (-1.61%)
NIO   9.06 (-2.27%)
BABA   86.80 (+0.32%)
AMD   97.86 (-2.41%)
T   18.60 (+0.76%)
F   11.48 (+0.53%)
MU   61.09 (-0.41%)
CGC   1.92 (+0.52%)
GE   91.04 (-0.60%)
DIS   94.16 (-1.74%)
AMC   4.42 (-1.12%)
PFE   40.43 (+0.62%)
PYPL   73.69 (+1.56%)
NFLX   330.31 (+3.10%)
S&P 500   3,967.71 (+0.48%)
DOW   32,210.87 (+0.33%)
QQQ   310.45 (+0.23%)
AAPL   159.76 (+0.52%)
MSFT   279.75 (+0.75%)
META   206.10 (+0.89%)
GOOGL   105.25 (-0.33%)
AMZN   98.09 (-0.63%)
TSLA   190.11 (-1.10%)
NVDA   267.53 (-1.61%)
NIO   9.06 (-2.27%)
BABA   86.80 (+0.32%)
AMD   97.86 (-2.41%)
T   18.60 (+0.76%)
F   11.48 (+0.53%)
MU   61.09 (-0.41%)
CGC   1.92 (+0.52%)
GE   91.04 (-0.60%)
DIS   94.16 (-1.74%)
AMC   4.42 (-1.12%)
PFE   40.43 (+0.62%)
PYPL   73.69 (+1.56%)
NFLX   330.31 (+3.10%)
S&P 500   3,967.71 (+0.48%)
DOW   32,210.87 (+0.33%)
QQQ   310.45 (+0.23%)
AAPL   159.76 (+0.52%)
MSFT   279.75 (+0.75%)
META   206.10 (+0.89%)
GOOGL   105.25 (-0.33%)
AMZN   98.09 (-0.63%)
TSLA   190.11 (-1.10%)
NVDA   267.53 (-1.61%)
NIO   9.06 (-2.27%)
BABA   86.80 (+0.32%)
AMD   97.86 (-2.41%)
T   18.60 (+0.76%)
F   11.48 (+0.53%)
MU   61.09 (-0.41%)
CGC   1.92 (+0.52%)
GE   91.04 (-0.60%)
DIS   94.16 (-1.74%)
AMC   4.42 (-1.12%)
PFE   40.43 (+0.62%)
PYPL   73.69 (+1.56%)
NFLX   330.31 (+3.10%)
S&P 500   3,967.71 (+0.48%)
DOW   32,210.87 (+0.33%)
QQQ   310.45 (+0.23%)
AAPL   159.76 (+0.52%)
MSFT   279.75 (+0.75%)
META   206.10 (+0.89%)
GOOGL   105.25 (-0.33%)
AMZN   98.09 (-0.63%)
TSLA   190.11 (-1.10%)
NVDA   267.53 (-1.61%)
NIO   9.06 (-2.27%)
BABA   86.80 (+0.32%)
AMD   97.86 (-2.41%)
T   18.60 (+0.76%)
F   11.48 (+0.53%)
MU   61.09 (-0.41%)
CGC   1.92 (+0.52%)
GE   91.04 (-0.60%)
DIS   94.16 (-1.74%)
AMC   4.42 (-1.12%)
PFE   40.43 (+0.62%)
PYPL   73.69 (+1.56%)
NFLX   330.31 (+3.10%)
NASDAQ:SOPH

SOPHiA GENETICS - SOPH Stock Forecast, Price & News

$4.13
-0.29 (-6.56%)
(As of 03/24/2023 03:31 PM ET)
Add
Compare
Today's Range
$4.13
▼
$4.50
50-Day Range
$2.27
▼
$5.49
52-Week Range
$1.68
▼
$8.44
Volume
89,318 shs
Average Volume
137,073 shs
Market Capitalization
$261.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

SOPHiA GENETICS MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
51.5% Upside
$6.33 Price Target
Short Interest
Healthy
0.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of SOPHiA GENETICS in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.06) to ($0.90) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

436th out of 989 stocks

Biological Products, Except Diagnostic Industry

73rd out of 166 stocks

See Top Rated MarketRank™ Stocks Here

SOPH stock logo

About SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SOPH Stock News Headlines

March 22, 2023 | marketwatch.com
AI Medicine Software Market 2023 Size Industry, Current Trends, Demand and Size Share Estimation by 2029 with Top Players
March 22, 2023 | marketwatch.com
Precision Medicine Software Market Size by 2031
March 24, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 21, 2023 | marketwatch.com
Genetic Testing for Cancer Risk Market Future Trends Outlook 2023, and Forecast to 2029 | Myriad Genetics, Inc., Invitae Corporation
March 21, 2023 | finance.yahoo.com
SOPHiA GENETICS SA (NASDAQ:SOPH) surges 23%; individual investors who own 44% shares profited along with institutions
March 17, 2023 | finance.yahoo.com
SOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?
March 16, 2023 | finance.yahoo.com
SOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?
March 14, 2023 | finance.yahoo.com
SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
March 24, 2023 | Investor Place Media (Ad)
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
March 9, 2023 | finance.yahoo.com
SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2022 Earnings Call Transcript
March 7, 2023 | finanznachrichten.de
SOPHiA GENETICS SA: SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
March 7, 2023 | msn.com
SOPHiA Genetics Non-GAAP EPS of -$0.17 beats by $0.13, revenue of $13.38M beats by $0.46M
March 7, 2023 | finance.yahoo.com
SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
March 7, 2023 | finance.yahoo.com
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
March 7, 2023 | msn.com
Supreme Court rules no genetic tests to find origin of wrongly implanted embryo
March 6, 2023 | markets.businessinsider.com
Here's what Wall Street expects from SOPHiA GENETICS SA's earnings report
March 6, 2023 | finance.yahoo.com
University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers
March 3, 2023 | finance.yahoo.com
SOPHiA GENETICS Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
March 1, 2023 | marketwatch.com
NGS Informatics and Clinical Genomics Market Industry Analysis, Estimates Size and Projections by 2029
March 1, 2023 | reuters.com
S.Africa's Aspen set for deals to revive idled production lines
March 1, 2023 | finance.yahoo.com
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
March 1, 2023 | finance.yahoo.com
Qiagen partners with Sophia Genetics on next-generation sequencing kits
March 1, 2023 | seekingalpha.com
SOPH SOPHiA GENETICS SA
February 28, 2023 | finance.yahoo.com
Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
February 23, 2023 | finance.yahoo.com
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023
February 15, 2023 | marketwatch.com
Hereditary Testing Market Five-year Assessment with Latest Technology Analysis [113+ Pages Report]
February 13, 2023 | finance.yahoo.com
SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
See More Headlines
Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SOPH Company Calendar

Last Earnings
11/10/2021
Today
3/24/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SOPH
CUSIP
N/A
CIK
1840706
Web
www.sophiagenetics.com
Phone
41-21-694-1060
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+53.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-87,450,000.00
Net Margins
-183.87%
Pretax Margin
-184.16%
Return on Equity
-39.48%
Return on Assets
-32.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.32
Quick Ratio
7.13

Sales & Book Value

Annual Sales
$47.56 million
Price / Sales
5.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.16 per share
Price / Book
1.31

Miscellaneous

Outstanding Shares
63,340,000
Free Float
60,247,000
Market Cap
$261.59 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Dr. Jurgi Camblong M.B.A. (Age 44)
    Ph.D., Co-Founder, CEO & Director
  • Mr. Ross Jordan Muken B.Sc. (Age 43)
    Sr. VP & CFO
  • Mr. Abhimanyu Verma
    Sr. VP & CTO
  • Dr. Zhenyu Xu Ph.D. (Age 41)
    Sr. VP & Chief Scientific Officer
  • Jennifer Pottage
    Head of Investor Relations
  • Mr. Daan van Well L.L.M. (Age 49)
    M.B.A., Sr. VP, Chief Legal Officer & Gen. Counsel
  • Ms. Manuela Da Silva Valente B.A. (Age 53)
    Sr. VP & Chief People Officer
  • Dr. Thierry Colin
    Sr. VP of Radiomics Bus. Area
  • Dr. Philippe Menu M.B.A. (Age 42)
    M.D., Ph.D., Sr. VP & Chief Medical Officer
  • Ms. Lara Hashimoto
    Sr. VP & Chief Bus. Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SOPH Stock - Frequently Asked Questions

Should I buy or sell SOPHiA GENETICS stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SOPH shares.
View SOPH analyst ratings or view top-rated stocks.

What is SOPHiA GENETICS's stock price forecast for 2023?

3 equities research analysts have issued twelve-month target prices for SOPHiA GENETICS's stock. Their SOPH share price forecasts range from $2.00 to $11.00. On average, they predict the company's stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price.
View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts.

How have SOPH shares performed in 2023?

SOPHiA GENETICS's stock was trading at $2.06 at the beginning of 2023. Since then, SOPH stock has increased by 100.5% and is now trading at $4.13.
View the best growth stocks for 2023 here.

Are investors shorting SOPHiA GENETICS?

SOPHiA GENETICS saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 34,400 shares, a decline of 17.7% from the February 13th total of 41,800 shares. Based on an average daily volume of 79,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are sold short.
View SOPHiA GENETICS's Short Interest.

When is SOPHiA GENETICS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our SOPH earnings forecast.

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.08. The business earned $10.36 million during the quarter, compared to the consensus estimate of $10.25 million. SOPHiA GENETICS had a negative net margin of 183.87% and a negative trailing twelve-month return on equity of 39.48%.

What ETF holds SOPHiA GENETICS's stock ?

BlackRock Future Health ETF holds 619 shares of SOPH stock, representing 0.03% of its portfolio.

What guidance has SOPHiA GENETICS issued on next quarter's earnings?

SOPHiA GENETICS issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $61.83M-, compared to the consensus revenue estimate of $62.57 million.

When did SOPHiA GENETICS IPO?

(SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

What is SOPHiA GENETICS's stock symbol?

SOPHiA GENETICS trades on the NASDAQ under the ticker symbol "SOPH."

Who are SOPHiA GENETICS's major shareholders?

SOPHiA GENETICS's stock is owned by a number of institutional and retail investors. Top institutional investors include Banque Pictet & Cie SA (3.45%), Credit Suisse AG (3.09%), Principal Financial Group Inc. (2.20%), Jennison Associates LLC (1.91%), General Electric Co. (1.75%) and Price T Rowe Associates Inc. MD (1.45%).

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SOPHiA GENETICS's stock price today?

One share of SOPH stock can currently be purchased for approximately $4.13.

How much money does SOPHiA GENETICS make?

SOPHiA GENETICS (NASDAQ:SOPH) has a market capitalization of $261.59 million and generates $47.56 million in revenue each year. The company earns $-87,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does SOPHiA GENETICS have?

The company employs 518 workers across the globe.

How can I contact SOPHiA GENETICS?

The official website for the company is www.sophiagenetics.com. The company can be reached via phone at 41-21-694-1060.

This page (NASDAQ:SOPH) was last updated on 3/24/2023 by MarketBeat.com Staff